Drug Science stands by its e-cigarette analysis from 2014, any way of radically reducing the death toll from tobacco would be a worldwide public health triumph. e-cigarettes are not the solution to end the ever-increasing death toll caused by tobacco. However, they have proven to be an incredibly effective tool for tens of thousands of …
Today (13th August 2019), the independent scientific body Drug Science has responded with disappointment to a decision by the National Institute for Health and Care Excellence (NICE), relating to cannabis-related medical products. In November 2018, the then Home Secretary Sajid Javid introduced regulations so that cannabis-derived medicinal products would be available on prescription. This change …
Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder (AUD). At this stage, eleven participants have completed the full 8-week MDMA-assisted …
The Royal College of Psychiatrists has undertaken a review to develop a College position on cannabis use in the UK and how this relates to mental health, incorporating evidence on the biological, psychological and social effects of cannabis, and the use of medicinal cannabis in relation to mental illness. The review invited comment from experts …
Drug Science will launch the Working Medical Cannabis Working Group at its House of Lords annual evening reception on Wednesday 22 May 2019.
Around the world, politicians are working to ban e-cigarette marketing, limit their nicotine content, prohibit use in public buildings, and even to ban them entirely. There remains a need for policy makers to become better informed of the relative harms of nicotine delivery systems in order to build a regulatory framework that minimises harm. The …
The first comprehensive review of the drug since its classification, DrugScience’s ketamine review highlighted harms such as neurological and bladder damage. Read it here
An assessment of the various harms of drugs used recreationally in the UK using multi-criteria decision analysis (MCDA) – a method that uses relevant experts’ knowledge and experience to assess the actual and relative harms – download the paper here. You can also download the raw data here. We wanted to assess drugs in terms …
